Objective: tcompare the decrease in pain in patients with pregabalin therapy versus interventional blocks. Materials and methods: retrospective cohort study that included patients older than 18 years diagnosed with neuropathic pain from a reference center in Pereira, Colombia, between the years 2010-2016. The outcome was assessed at three months in each cohort and was defined as the change in pain intensity according to the visual analog pain scale. The comparison between cohorts and the effectiveness of the intervention was evaluated through repeated measures analysis with the generalized estimating equation. Results: a total of 1451 patients with pain were selected, of these, only 94 met the inclusion criteria. Sixty-two (66%) patients received a pharmacological scheme with pregabalin, and 32 patients (34%) underwent blockages. The pain intensity prior to pregabalin treatment was 7.3 �...

We have recently read the article by Chaung et al1 describing a case of SARS‐CoV‐2 and HCoV‐HKU1 coinfection. The HCoV‐HKU1 is also a member of the Betacoronavirus. In addition to other coronaviruses in different regions of the world, there is an increasing number of reports of coinfections in SARS‐CoV‐2/COVID‐19. Then, we would like to take the opportunity to discuss some of them,1-10 as there are not yet reviews on this emerging issue of COVID‐19. Currently, the evidence suggests that the coinfection rates between SARS‐CoV‐2 and other respiratory pathogens would be higher than initially expected, which represents a challenge for the diagnosis and treatment.